Press Releases Details


Thomson CompuMark’s New Global Pharmaceutical Search Reduces Risk of Drug Approval Delays by Identifying Potentially Conflicting Trademarks in International Markets.


NORTH QUINCY, Mass. (January 13, 2012) – Thomson CompuMark, the global leader in trademark searching and brand protection solutions and part of Thomson Reuters (NYSE:TRI), today announced the launch of its new Global Pharmaceutical Search, providing targeted, global trademark intelligence in a single online report.

Avoiding potential confusion among pharmaceutical brands, which can lead to prescription errors, is a critically important public health concern. To address this, regulatory bodies in the U.S. and Europe have implemented rigorous processes for evaluating and approving pharmaceutical brand names. Searching globally for confusingly similar trademarks early in the process is important to minimize the chance of name rejection—a costly misstep.

New Global Pharmaceutical Search addresses this critical need. It leverages Thomson CompuMark’s industry-leading global trademark content—including common law and web content—to give brand owners comprehensive, yet concise, information on trademark availability from key pharmaceutical markets in a single report.

Search coverage includes Thomson CompuMark’s proprietary, quality checked trademark office records, web and domain name coverage, and US and European Regulatory and industry specific sources, including pharmaceutical names in use. Brand owners can select the registers that match their product strategy, including the U.S., U.K., Spain, France, Germany, Switzerland, Italy, Benelux, and Canada.

Designed to save users valuable time, Global Pharmaceutical Search results are delivered online, on SERION®. This easy-to-use online analysis tool enables users to rapidly pinpoint potential conflicts, perform follow-up research on marks of interest with a single click, and create and share custom reports on their findings in seconds.

“In today’s global pharmaceutical marketplace, brand owners need the most complete, global view of the trademark landscape to minimize business risk,” said Anne Olson, Vice President Global Operations of Thomson CompuMark. “Our new Global Pharmaceutical Search provides that insight in a single, concise report that facilitates more informed decisions in less time. It’s just another way we’re using our global trademark expertise to help our customers launch the pharmaceuticals patients need faster and more efficiently.

Olson noted that Thomson CompuMark also shares its global trademark expertise through industry leading publications, including a recent Special Report on Pharmaceutical Trademark Trends. This report provides an overview of global pharmaceutical trademark trends, regulatory changes and clearance challenges, as well as best practices for selecting, researching and clearing new pharmaceutical brands. Visit the Thomson CompuMark website to request a copy of this Special Report.


Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 55,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges (symbol: TRI). For more information, go to

To find out more about IP Solutions from Thomson Reuters, go to

# # # 


Victoria Poor
Marketing Communications Manager, Thomson CompuMark


Post new comment

The content of this field is kept private and will not be shown publicly.
  • Allowed HTML tags: <ul> <ol> <li> <p>
  • Lines and paragraphs break automatically.

More information about formatting options

Your comment will be submitted for review and should appear shortly.